SEC Comment Letter for NUGENEREX IMMUNO-ONCOLOGY, INC. (CIK 0001804585) — May 6, 2020
NUGENEREX IMMUNO-ONCOLOGY, INC. (CIK 0001804585)
Date: May 6, 2020 · CIK: 0001804585 · Accession: 0000000000-20-003948
AI Filing Summary & Sentiment
File numbers found in text: 000-56153
Letter
United States securities and exchange commission logo May 5, 2020 Joseph Moscato Chief Executive Officer NuGenerex Immuno-Oncology, Inc. 10102 USA Today Way Miramar, FL 33025 Re:NuGenerex Immuno-Oncology, Inc. Registration Statement on Form 10-12G Filed March 12, 2020 File No. 000-56153 Dear Mr. Moscato: We issued comments to you on the above captioned filing on April 8, 2020. As of the date of this letter, these comments remain outstanding and unresolved. We expect you to provide a complete, substantive response to these comments by May 19, 2020. If you do not respond, we will, consistent with our obligations under the federal securities laws, decide how we will seek to resolve material outstanding comments and complete our review of your filing and your disclosure. Among other things, we may decide to release publicly, through the agency's EDGAR system, all correspondence, including this letter, relating to the review of your filings, consistent with the staff's decision to publicly release comment and response letters relating to disclosure filings it has reviewed. Please contact Ada Sarmento at (202) 551-3798 or Joe McCann at (202) 551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Wofford, Esq.
Show Raw Text
United States securities and exchange commission logo
May 5, 2020
Joseph Moscato
Chief Executive Officer
NuGenerex Immuno-Oncology, Inc.
10102 USA Today Way
Miramar, FL 33025
Re:NuGenerex Immuno-Oncology, Inc.
Registration Statement on Form 10-12G
Filed March 12, 2020
File No. 000-56153
Dear Mr. Moscato:
We issued comments to you on the above captioned filing on April 8, 2020. As of the
date of this letter, these comments remain outstanding and unresolved. We expect you to
provide a complete, substantive response to these comments by May 19, 2020.
If you do not respond, we will, consistent with our obligations under the federal securities
laws, decide how we will seek to resolve material outstanding comments and complete our
review of your filing and your disclosure. Among other things, we may decide to release
publicly, through the agency's EDGAR system, all correspondence, including this letter, relating
to the review of your filings, consistent with the staff's decision to publicly release comment and
response letters relating to disclosure filings it has reviewed.
Please contact Ada Sarmento at (202) 551-3798 or Joe McCann at (202) 551-6262 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey Wofford, Esq.